BRPI0916885B8 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BRPI0916885B8
BRPI0916885B8 BRPI0916885A BRPI0916885A BRPI0916885B8 BR PI0916885 B8 BRPI0916885 B8 BR PI0916885B8 BR PI0916885 A BRPI0916885 A BR PI0916885A BR PI0916885 A BRPI0916885 A BR PI0916885A BR PI0916885 B8 BRPI0916885 B8 BR PI0916885B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
cephthalorine
prodrug
solvate
alone
Prior art date
Application number
BRPI0916885A
Other languages
English (en)
Inventor
Biek Donald
Original Assignee
Astrazeneca Ab
Pfizer Anti Infectives Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41721943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916885(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Pfizer Anti Infectives Ab filed Critical Astrazeneca Ab
Publication of BRPI0916885A2 publication Critical patent/BRPI0916885A2/pt
Publication of BRPI0916885B1 publication Critical patent/BRPI0916885B1/pt
Publication of BRPI0916885B8 publication Critical patent/BRPI0916885B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica, e, método para tratar uma infecção bacteriana. a presente invenção fornece composições compreendendo ceftalorine ou um seu sal, seu solvato ou uma sua pró-droga farmaceuticamente aceitável sozinho(a) ou em combinação com um agente antibacteriano. a presente invenção fornece métodos de tratamento de infecção bacteriana, que inclui administrar uma quantidade eficaz de ceftalorine ou de um seu sal, seu solvato ou uma sua pró-droga farmaceuticamente aceitável sozinho( a) ou em combinação com um agente antibacteriano.
BRPI0916885A 2008-08-28 2009-08-28 composição farmacêutica BRPI0916885B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9249708P 2008-08-28 2008-08-28
PCT/US2009/055306 WO2010025328A1 (en) 2008-08-28 2009-08-28 Compositions and methods of treatment comprising ceftaroline

Publications (3)

Publication Number Publication Date
BRPI0916885A2 BRPI0916885A2 (pt) 2017-06-20
BRPI0916885B1 BRPI0916885B1 (pt) 2019-12-03
BRPI0916885B8 true BRPI0916885B8 (pt) 2021-05-25

Family

ID=41721943

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916885A BRPI0916885B8 (pt) 2008-08-28 2009-08-28 composição farmacêutica

Country Status (10)

Country Link
US (1) US20100197650A1 (pt)
EP (2) EP2328569A4 (pt)
KR (2) KR101783573B1 (pt)
CN (2) CN102292079B (pt)
AU (1) AU2009285632A1 (pt)
BR (1) BRPI0916885B8 (pt)
ES (1) ES2718535T3 (pt)
MX (2) MX2011002185A (pt)
RU (1) RU2524665C2 (pt)
WO (1) WO2010025328A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2714034T3 (pl) 2011-05-28 2018-12-31 Wockhardt Limited Kompozycje zawierające cefepim i tazobaktam
ES2721623T3 (es) 2012-10-19 2019-08-02 Sandoz Ag Procedimiento novedoso para la preparación de ceftarolina fosamil
JP2016501903A (ja) * 2012-12-20 2016-01-21 サンド・アクチエンゲゼルシヤフト 新規結晶形のセフタロリンフォサミル
WO2014138302A1 (en) 2013-03-05 2014-09-12 University Of Notre Dame Quinazolinone antibiotics
WO2014167575A2 (en) * 2013-03-26 2014-10-16 Astron Research Limited Stable tigecycline composition
IN2013MU01127A (pt) 2013-03-26 2015-05-01 Astron Res Ltd
EP4112057A1 (en) 2015-07-09 2023-01-04 Washington University Compositions and methods of use of antibacterial drug combinations
WO2017010382A1 (ja) * 2015-07-14 2017-01-19 国立大学法人大阪大学 筋強直性ジストロフィー治療薬
CN106491537A (zh) * 2016-12-02 2017-03-15 瑞阳制药有限公司 包含头孢洛林酯的注射用无菌粉末及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
PT1310502E (pt) * 2000-08-10 2009-07-31 Takeda Pharmaceutical Composto de fosfonocefem
EP1618894B1 (en) * 2003-04-28 2018-06-13 Takeda Pharmaceutical Company Limited Composition for injection
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations

Also Published As

Publication number Publication date
EP2889034A3 (en) 2015-10-14
RU2011111588A (ru) 2012-10-10
EP2889034B1 (en) 2019-02-27
EP2889034A2 (en) 2015-07-01
EP2328569A4 (en) 2012-12-26
BRPI0916885B1 (pt) 2019-12-03
WO2010025328A1 (en) 2010-03-04
RU2524665C2 (ru) 2014-07-27
MX372951B (es) 2020-04-02
CN102292079A (zh) 2011-12-21
CN103212076A (zh) 2013-07-24
EP2328569A1 (en) 2011-06-08
MX2011002185A (es) 2011-04-04
KR101783573B1 (ko) 2017-09-29
BRPI0916885A2 (pt) 2017-06-20
US20100197650A1 (en) 2010-08-05
HK1211472A1 (en) 2016-05-27
KR101787113B1 (ko) 2017-11-15
KR20110059725A (ko) 2011-06-03
AU2009285632A1 (en) 2010-03-04
ES2718535T3 (es) 2019-07-02
KR20160084482A (ko) 2016-07-13
CN102292079B (zh) 2014-03-12

Similar Documents

Publication Publication Date Title
BR112013005426A2 (pt) "composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação."
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR112014000665A2 (pt) composto, uso do mesmo, composição farmacêutica, agente antimicrobiano, e, método para previnir ou tratar uma infecção bacteriana
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
EP2590978A4 (en) CARBAPENEM ANTIBACTERIA WITH GRAM NEGATIVE ACTIVITY
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX2014003430A (es) Una composicion y un metodo para tratar una enfermedad autoinmune.
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
MX2009003912A (es) Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: PFIZER ANTI-INFECTIVES AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2737 DE 20-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.